Statin-Associated Diabetes Risk

Risk by Statin Intensity

Approximately 1-5% of patients on statins develop new-onset diabetes over 4-5 years of treatment, with the risk varying substantially by statin intensity and baseline diabetes risk factors, according to The Lancet Diabetes and Endocrinology 1, 2
Annual incidence of diabetes is 0.1-0.3% per year for moderate-intensity statins 1
Over 4 years of treatment, approximately 1.2-1.5% of patients on moderate-intensity statins develop diabetes compared to 1.2% on placebo, as reported by Diabetes Care 3, 4
This translates to one additional case of diabetes per 255 patients treated for 4 years with moderate-intensity statins 3, 4, 5
Annual incidence of diabetes is 1.27-1.36% per year excess risk for high-intensity statins 1, 2
Approximately 4.8% of patients on high-intensity statins develop diabetes over follow-up compared to 3.5% on placebo, according to The Lancet Diabetes and Endocrinology 2
This represents a 36% relative increase in new-onset diabetes (RR 1.36, 95% CI 1.25-1.48) for high-intensity statins 1, 2

Statins cause modest increases in glucose and HbA1c levels, with mean glucose increase of 0.04-0.12 mmol/L for moderate-intensity and 0.22 mmol/L for high-intensity statins 1
Mean HbA1c increase is 0.06-0.09% for moderate-intensity and 0.08% for high-intensity statins 1
Among patients with existing diabetes, statins cause a 10% relative increase in worsening glycemia with moderate-intensity and 24% increase with high-intensity therapy 1

Approximately 62-67% of excess diabetes cases occur in patients in the highest quartile of baseline glycemia, regardless of statin intensity, according to The Lancet Diabetes and Endocrinology 1
Patients with pre-existing diabetes risk factors have substantially higher absolute risk, as reported by the Journal of the American College of Cardiology 6
Statins appear to accelerate diabetes diagnosis by approximately 5 weeks in predisposed individuals rather than causing de novo diabetes, according to the Journal of the American College of Cardiology 6

The cardiovascular benefits overwhelmingly outweigh diabetes risk, with 5.4 cardiovascular events prevented for every one case of diabetes induced over 4 years, as reported by Diabetes Care 3, 4, 5
Alternative estimates suggest 5-9 ASCVD events prevented per case of diabetes, according to the Journal of the American College of Cardiology 6
For every 100-150 people treated with statins, one cardiovascular event is prevented, while 500 people must be treated to cause one new case of diabetes, as reported by the Journal of the American College of Cardiology 6

The American College of Cardiology recommends not withholding statins due to diabetes risk in patients with cardiovascular indications, and implementing regular glucose monitoring for patients at high diabetes risk requiring statins 7
Emphasize lifestyle interventions (weight loss, exercise) to mitigate diabetes risk, as recommended by the Journal of the American College of Cardiology and the American College of Cardiology 6, 7

The American Diabetes Association recommends that the risk of statin-induced diabetes should not deter appropriate statin use for cardiovascular risk reduction in patients with pre-diabetes 8, 9

For every one case of diabetes induced by statins, 5.4 cardiovascular events are prevented over 4 years, according to the American College of Cardiology 8, 9
Statin therapy reduces major cardiovascular events by 30% (hazard ratio 0.70) in pre-diabetic patients, as recommended by the American Heart Association 10, 11

The American College of Cardiology recommends initiating moderate-intensity statin therapy (atorvastatin 10-20 mg, rosuvastatin 5-10 mg) in pre-diabetic patients aged 40-75 years with one or more cardiovascular risk factors 10, 12
High-intensity statin therapy (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) is recommended if 10-year cardiovascular risk is ≥10% or if multiple cardiovascular risk factors are present, as suggested by the American Diabetes Association 10, 12

Regular glucose monitoring (fasting glucose or HbA1c) every 6-12 months is recommended for pre-diabetic patients on statin therapy, according to the American Association of Clinical Endocrinologists 10, 11
Target LDL cholesterol <100 mg/dL for primary prevention, <70 mg/dL if additional cardiovascular risk factors present, as recommended by the American College of Cardiology 10, 11

The Heart Protection Study demonstrated a 33% risk reduction in cardiovascular events with simvastatin in diabetic patients without symptomatic vascular disease, as reported by the European Society of Cardiology 13, 14
Meta-analyses of over 18,000 diabetic patients show a 9% reduction in all-cause mortality and 13% reduction in vascular mortality for each 39 mg/dL reduction in LDL cholesterol, according to the American Diabetes Association 10